On Wednesday, Windtree Therapeutics, Inc. (WINT) released promising topline results from its Phase 2b SEISMiC Extension Study of istaroxime, a potential treatment for patients in early cardiogenic shock due to heart failure. This study focused on the effects of istaroxime on critical measures like blood pressure, cardiac function, and other vital parameters over a 96-hour period of close monitoring, with a final follow-up at 30 days.
The study achieved its primary endpoint by significantly improving systolic blood pressure within six hours. Notably, the group receiving istaroxime demonstrated significantly better results than the placebo group. Systolic blood pressure, which is the pressure in arteries when the heart contracts and pumps blood, is a crucial indicator of heart health.
Encouragingly, the study also revealed significant benefits across various secondary endpoints. The safety profile of istaroxime was deemed favorable and consistent with previous clinical trials.
Further details of the study results, including additional measures of efficacy and safety, along with individual istaroxime dosing group data, are scheduled to be presented at the Heart Failure Society of America Meeting on September 30.
Craig Fraser, Chairman and CEO of Windtree, expressed optimism, stating, “Across four Phase 2 studies to date, istaroxime has demonstrated a highly unique and attractive profile as a potential therapy for cardiogenic shock and acute heart failure patients. We are excited to share the details of study results next week and to continuing to progress istaroxime towards Phase 3 readiness for cardiogenic shock.”
Following this news, WINT stock experienced a decline of 7.98% to $3 during the premarket session on Wednesday.
